

Neurotech

25 October 2017

CORRECTION TO ANNOUNCEMENT RE PLACEMENT

Neurotech International Limited (“Neurotech” or the “Company”) (ASX: NTI) advises that its earlier announcement of 25 October 2017 incorrectly stated the total number of unlisted options on issue following completion of the first tranche of the placement.

The issued capital of Neurotech following completion of the first tranche of the placement is:

- 72,753,320 ordinary fully paid shares
- 28,487,058 restricted ordinary fully paid shares
- 10,894,390 unlisted options

-ends-

About Neurotech

Neurotech International Limited is a medical device and solutions company incorporated in Australia and operating through its wholly-owned, Malta-based subsidiary AAT Research Limited. Neurotech’s primary mission is to improve the lives of people with neurological conditions, with a vision of becoming the global leader in home-use and clinical neurotechnology solutions that are both accessible and affordable. Through flagship device Mente Autism and its associated platform, Neurotech is focused on the development and commercialisation of technological solutions for the diagnosis and treatment of such conditions, starting with autism.

Mente Autism is a clinical-quality EEG device that uses neurofeedback technology to help children with ASD. Designed for home use, Mente Autism helps relax the minds of children on the spectrum which in turns helps them to focus better and engage positively with their environment.

For more information about Neurotech and Mente Autism please visit:

<http://www.neurotechinternational.com>.

<http://www.mentetech.com>.

For more information please contact:

Matthew Wright

matt@nwrcommunications.com.au

Tel: +61 451 896 420

Neurotech International Ltd

ABN 73 610 205 402

Level 14, 191 St Georges Terrace

Perth, Western Australia 6060

www.neurotechinternational.com